Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Income from Continuing Operations (2024 - 2025)

Indivior Pharmaceuticals has reported Income from Continuing Operations over the past 2 years, most recently at 102000000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 102000000.0 for Q4 2025, up 385.71% from a year ago — trailing twelve months through Dec 2025 was 210000000.0 (up 2900.0% YoY), and the annual figure for FY2025 was 210000000.0, up 2900.0%.
  • Income from Continuing Operations for Q4 2025 was 102000000.0 at Indivior Pharmaceuticals, up from 42000000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for INDV hit a ceiling of 102000000.0 in Q4 2025 and a floor of 98000000.0 in Q2 2024.